Skip to content

West Pharmaceutical Services

US · WST #752 by market cap Listed 1970
390.30 -6.39 -1.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Visteon Is Maintained at Buy by UBS
    Dow Jones · 2026/10/24
  • Company notice
    Visteon | 8-K: Visteon Announces Third Quarter 2026 Financial Results
    SEC · 2026/10/22
  • Rating change
    Citi Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Maintains Target Price $494
    Market Newswire · 2026/10/30
  • Press Release: Visteon Declares Quarterly Dividend of $0.375 Per Share
    Dow Jones · 2026/11/17
  • Rating change
    A Quick Look at Today's Ratings for Visteon(VC.US), With a Forecast Between $95 to $135
    Market Newswire · 2026/10/24
  • RBC Capital Maintains Visteon(VC.US) With Buy Rating, Raises Target Price to $102
    Market Newswire · 2026/11/13
  • Visteon To Go Ex-Dividend On December 1st, 2026 With 0.375 USD Dividend Per Share
    Market Newswire · 2026/11/18
  • Rating change
    Barclays Maintains Overweight on Visteon, Lowers Price Target to $105
    Benzinga · 2026/10/29
  • Company notice
    10-Q: Visteon | 10-Q: Q2 2026 Earnings Report
    SEC · 2026/7/23
  • Rating change
    Citi Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $494
    Market Newswire · 2026/10/30
  • Company notice
    Visteon | 8-K: Current report
    SEC · 2026/10/28
  • Rating change
    UBS Maintains Buy on Visteon, Lowers Price Target to $96
    Benzinga · 2026/10/24
  • A Quick Look at Today's Ratings for West Pharmaceutical Services(WST.US), With a Forecast Between $480 to $500
    Market Newswire · 2026/10/31
  • J.P. Morgan Maintains Visteon(VC.US) With Buy Rating, Maintains Target Price $135
    Market Newswire · 2026/11/10
  • Company notice
    Visteon | SCHEDULE 13G/A: Others
    SEC · 2026/10/7
  • Company notice
    Visteon | 10-Q: Q3 2026 Earnings Report
    SEC · 2026/10/22
  • Rating change
    Barclays Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $500
    Market Newswire · 2026/10/30
  • Rating change
    Visteon Is Maintained at Overweight by JP Morgan
    Dow Jones · 2026/10/24
  • Rating change
    Visteon Is Maintained at Overweight by Barclays
    Dow Jones · 2026/10/29
  • Rating change
    Barclays Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $105
    Market Newswire · 2026/10/28
  • Rating change
    RBC Capital Maintains Outperform on Visteon, Lowers Price Target to $100
    Benzinga · 2026/10/23
  • Rating change
    Visteon Is Maintained at Outperform by RBC Capital
    Dow Jones · 2026/10/23
  • Rating change
    Visteon Price Target Cut to $135.00/Share From $145.00 by JP Morgan
    Dow Jones · 2026/10/24
  • Rating change
    JP Morgan Maintains Overweight on Visteon, Lowers Price Target to $135
    Benzinga · 2026/10/24
  • Rating change
    Barclays Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $440
    Market Newswire · 2026/10/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

West Pharmaceutical Services discussion 0 comments

Add a comment